Early Data Show Promise with Adaptimmune's T-Cell Platform
By Nuala Moran
Wednesday, November 21, 2012
LONDON Adaptimmune Ltd. has published the first clinical data on its genetically modified T-cell technology, saying infusion of the engineered cells is safe, well tolerated and leads to a high response rate in a high-risk multiple myeloma population.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.